{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:16:19Z","timestamp":1779210979540,"version":"3.51.4"},"reference-count":119,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"am","delay-in-days":393,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.neurol.2022.03.008","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T17:09:24Z","timestamp":1651165764000},"page":"472-483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Biomarkers and diagnosis of dementia with Lewy bodies including prodromal: Practical aspects"],"prefix":"10.1016","volume":"178","author":[{"given":"F.","family":"Blanc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6786-3191","authenticated-orcid":false,"given":"O.","family":"Bousiges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.neurol.2022.03.008_bib0600","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/ageing\/afi190","article-title":"A systematic review of prevalence and incidence studies of dementia with Lewy bodies","volume":"34","author":"Zaccai","year":"2005","journal-title":"Age Ageing"},{"issue":"17","key":"10.1016\/j.neurol.2022.03.008_bib0605","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","article-title":"Research criteria for the diagnosis of prodromal dementia with Lewy bodies","volume":"94","author":"McKeith","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib0610","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.03.008_bib0615","first-page":"434","article-title":"Cognitive profile in prodromal disease (dementia) with Lewy bodies","volume":"15","author":"Kemp","year":"2017","journal-title":"Geriatr Psychol Neuropsychiatr Vieil"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib0620","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13195-017-0242-1","article-title":"Cognitive profile in prodromal dementia with Lewy bodies","volume":"9","author":"Kemp","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"10.1016\/j.neurol.2022.03.008_bib0625","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00401-020-02157-3","article-title":"The structural differences between patient-derived \u03b1-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies","volume":"139","author":"Van der Perren","year":"2020","journal-title":"Acta Neuropathologica"},{"issue":"3","key":"10.1016\/j.neurol.2022.03.008_bib0630","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00415-009-5324-y","article-title":"Low sensitivity in clinical diagnoses of dementia with Lewy bodies","volume":"257","author":"Nelson","year":"2010","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2022.03.008_bib0635","doi-asserted-by":"crossref","first-page":"e0127396","DOI":"10.1371\/journal.pone.0127396","article-title":"Cortical thickness in dementia with Lewy Bodies and Alzheimer's disease: a comparison of prodromal and dementia stages","volume":"10","author":"Blanc","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2022.03.008_bib0640","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13195-016-0198-6","article-title":"Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer's disease","volume":"8","author":"Blanc","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib0645","doi-asserted-by":"crossref","first-page":"9437","DOI":"10.1038\/s41598-017-08667-7","article-title":"Insular atrophy at the prodromal stage of dementia with Lewy bodies: a VBM DARTEL study","volume":"7","author":"Roquet","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurol.2022.03.008_bib0650","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.parkreldis.2021.03.011","article-title":"Hippocampal and insula volume in mild cognitive impairment with Lewy bodies","volume":"86","author":"Firbank","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"issue":"22","key":"10.1016\/j.neurol.2022.03.008_bib0655","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1212\/WNL.0000000000003371","article-title":"Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment","volume":"87","author":"Kantarci","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.03.008_bib0660","series-title":"Atrophy of insulae and hippocampi in prodromal dementia with Lewy bodies and Alzheimer's Disease: visual assessment ADPD","author":"Blanc","year":"2019"},{"issue":"Pt. 1","key":"10.1016\/j.neurol.2022.03.008_bib0665","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/brain\/awn298","article-title":"Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis","volume":"132","author":"Burton","year":"2009","journal-title":"Brain"},{"issue":"Pt. 4","key":"10.1016\/j.neurol.2022.03.008_bib0670","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/brain\/aww005","article-title":"MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases","volume":"139","author":"Harper","year":"2016","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib0675","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/JAD-180687","article-title":"Loss of swallow tail sign on susceptibility-weighted imaging in dementia with Lewy Bodies","volume":"67","author":"Rizzo","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"10.1016\/j.neurol.2022.03.008_bib0680","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3174\/ajnr.A5274","article-title":"MRI of the swallow tail sign: a useful marker in the diagnosis of Lewy Body Dementia?","volume":"38","author":"Shams","year":"2017","journal-title":"AJNR Am J Neuroradiol"},{"issue":"2","key":"10.1016\/j.neurol.2022.03.008_bib0685","first-page":"196","article-title":"Prodromal stage of disease (dementia) with Lewy bodies, how to diagnose in practice?","volume":"15","author":"Blanc","year":"2017","journal-title":"Geriatr Psychol Neuropsychiatr Vieil"},{"issue":"5","key":"10.1016\/j.neurol.2022.03.008_bib0690","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/WNL.56.5.643","article-title":"Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD","volume":"56","author":"Lobotesis","year":"2001","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.neurol.2022.03.008_bib0695","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1007\/s00259-002-0919-x","article-title":"Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies","volume":"29","author":"Pasquier","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.neurol.2022.03.008_bib0700","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s00259-005-1921-x","article-title":"Comparative value of brain perfusion SPECT and [123I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease","volume":"33","author":"Hanyu","year":"2006","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"7","key":"10.1016\/j.neurol.2022.03.008_bib0705","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s12149-017-1181-4","article-title":"Validation of the cingulate island sign with optimized ratios for discriminating dementia with Lewy bodies from Alzheimer's disease using brain perfusion SPECT","volume":"31","author":"Imabayashi","year":"2017","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.neurol.2022.03.008_bib0710","doi-asserted-by":"crossref","first-page":"568438","DOI":"10.3389\/fneur.2020.568438","article-title":"Differentiating Mild Cognitive Impairment, Alzheimer's Disease, and Dementia With Lewy bodies using cingulate island sign on perfusion IMP-SPECT","volume":"11","author":"Kanetaka","year":"2020","journal-title":"Front Neurol"},{"issue":"12","key":"10.1016\/j.neurol.2022.03.008_bib0715","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.2967\/jnumed.114.143347","article-title":"18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias","volume":"55","author":"O\u2019Brien","year":"2014","journal-title":"J Nucl Med"},{"issue":"1\u20132","key":"10.1016\/j.neurol.2022.03.008_bib0720","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0304-3940(97)00713-1","article-title":"Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography","volume":"235","author":"Imamura","year":"1997","journal-title":"Neurosci Lett"},{"issue":"10","key":"10.1016\/j.neurol.2022.03.008_bib0725","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2967\/jnumed.109.065870","article-title":"The 18F-FDG PET cingulate island sign and comparison to 123I-\u03b2-CIT SPECT for diagnosis of dementia with Lewy Bodies","volume":"50","author":"Lim","year":"2009","journal-title":"J Nuclear Med"},{"issue":"6","key":"10.1016\/j.neurol.2022.03.008_bib0730","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s12149-016-1076-9","article-title":"Cingulate island sign on FDG-PET is associated with medial temporal lobe atrophy in dementia with Lewy bodies","volume":"30","author":"Iizuka","year":"2016","journal-title":"Ann Nucl Med"},{"issue":"4","key":"10.1016\/j.neurol.2022.03.008_bib0735","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2967\/jnumed.116.179903","article-title":"(18)F-FDG PET in posterior cortical atrophy and dementia with Lewy Bodies","volume":"58","author":"Whitwell","year":"2017","journal-title":"J Nucl Med"},{"issue":"Pt 9","key":"10.1016\/j.neurol.2022.03.008_bib0740","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1093\/brain\/aws211","article-title":"Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias","volume":"135","author":"Colloby","year":"2012","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.neurol.2022.03.008_bib0745","first-page":"1176","article-title":"Dementia with Lewy bodies: a comparison of clinical diagnosis","volume":"78","author":"Walker","year":"2007","journal-title":"FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.neurol.2022.03.008_bib0750","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","article-title":"Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study","volume":"6","author":"McKeith","year":"2007","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.neurol.2022.03.008_bib0755","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1136\/jnnp-2012-302577","article-title":"Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT","volume":"83","author":"Morgan","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.neurol.2022.03.008_bib0760","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1007\/s00259-019-04480-8","article-title":"Diagnostic accuracy of DAT-SPECT and MIBG scintigraphy for dementia with Lewy bodies: an updated systematic review and Bayesian latent class model meta-analysis","volume":"47","author":"Nihashi","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.neurol.2022.03.008_bib0765","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1017\/S0033291718000995","article-title":"Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies","volume":"49","author":"Thomas","year":"2019","journal-title":"Psychol Med"},{"issue":"3","key":"10.1016\/j.neurol.2022.03.008_bib0770","doi-asserted-by":"crossref","first-page":"e0120540","DOI":"10.1371\/journal.pone.0120540","article-title":"Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study","volume":"10","author":"Yoshita","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2022.03.008_bib0775","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neurobiolaging.2016.04.026","volume":"52","author":"Sonni","year":"2017","journal-title":"Neurobiol Aging"},{"issue":"23","key":"10.1016\/j.neurol.2022.03.008_bib0780","doi-asserted-by":"crossref","first-page":"e2801","DOI":"10.1212\/WNL.0000000000012060","article-title":"Accuracy of cardiac innervation scintigraphy for mild cognitive impairment with Lewy Bodies","volume":"96","author":"Roberts","year":"2021","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.neurol.2022.03.008_bib0785","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3390\/ph14090847","article-title":"Alpha-Synuclein PET tracer development-an overview about current efforts","volume":"14","author":"Korat","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.neurol.2022.03.008_bib0790","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00259-020-05133-x","article-title":"[(11)C]MODAG-001-towards a PET tracer targeting \u03b1-synuclein aggregates","volume":"48","author":"Kuebler","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.neurol.2022.03.008_bib0795","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archneurol.2010.179","article-title":"Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people","volume":"67","author":"De Meyer","year":"2010","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2022.03.008_bib0800","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.neuint.2009.02.017","article-title":"Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P)","volume":"55","author":"Koopman","year":"2009","journal-title":"Neurochem Int"},{"issue":"12","key":"10.1016\/j.neurol.2022.03.008_bib0805","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1515\/CCLM.2006.258","article-title":"Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies","volume":"44","author":"Vanderstichele","year":"2006","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"10.1016\/j.neurol.2022.03.008_bib0810","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1515\/CCLM.2006.035","article-title":"Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies","volume":"44","author":"Mollenhauer","year":"2006","journal-title":"Clin Chem Lab Med"},{"issue":"1\u20132","key":"10.1016\/j.neurol.2022.03.008_bib0815","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jns.2014.07.015","article-title":"Assessment of CSF Abeta as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: a meta-analysis of 50 studies","volume":"345","author":"Tang","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2022.03.008_bib0820","first-page":"536538","article-title":"Cerebrospinal fluid biomarkers for dementia with lewy bodies","volume":"2010","author":"Mukaetova-Ladinska","year":"2010","journal-title":"Int J Alzheimers Dis"},{"issue":"9","key":"10.1016\/j.neurol.2022.03.008_bib0825","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1212\/WNL.54.9.1875","article-title":"Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies","volume":"54","author":"Kanemaru","year":"2000","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.neurol.2022.03.008_bib0830","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/archneur.60.12.1696","article-title":"Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?","volume":"60","author":"Clark","year":"2003","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.neurol.2022.03.008_bib0835","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/archneur.60.9.1218","article-title":"Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease","volume":"60","author":"Gomez-Tortosa","year":"2003","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.neurol.2022.03.008_bib0840","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00702-004-0235-7","article-title":"Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease","volume":"112","author":"Mollenhauer","year":"2005","journal-title":"J Neural Transm"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib0845","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s100720170055","article-title":"CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group","volume":"22","author":"Parnetti","year":"2001","journal-title":"Neurol Sci"},{"issue":"10","key":"10.1016\/j.neurol.2022.03.008_bib0850","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.biopsych.2008.02.016","article-title":"Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies","volume":"64","author":"Parnetti","year":"2008","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.neurol.2022.03.008_bib0855","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archneur.58.3.373","article-title":"Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice","volume":"58","author":"Andreasen","year":"2001","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib0860","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/JAD-130995","article-title":"Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease","volume":"38","author":"Kaerst","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.neurol.2022.03.008_bib0865","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1006\/bbrc.1997.6908","article-title":"Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology","volume":"236","author":"Arai","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.neurol.2022.03.008_bib0870","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1212\/WNL.56.4.576","article-title":"Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies","volume":"56","author":"Tschampa","year":"2001","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neurol.2022.03.008_bib0875","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/jnnp.2009.197483","article-title":"Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease","volume":"81","author":"Kasuga","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.neurol.2022.03.008_bib0880","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/156720510791383796","article-title":"The cerebrospinal fluid amyloid beta42\/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia","volume":"7","author":"Spies","year":"2010","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib0885","doi-asserted-by":"crossref","first-page":"e55328","DOI":"10.1371\/journal.pone.0055328","article-title":"Alterations of CSF cystatin C levels and their correlations with CSF Alphabeta40 and Alphabeta42 levels in patients with Alzheimer's disease, dementia with lewy bodies and the atrophic form of general paresis","volume":"8","author":"Zhong","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.neurol.2022.03.008_bib0890","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3233\/JAD-150731","article-title":"Diagnostic value of cerebrospinal fluid biomarkers (Phospho-Tau181, total-Tau, Abeta42, and Abeta40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies","volume":"51","author":"Bousiges","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neurol.2022.03.008_bib0895","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jnnp-2017-316385","article-title":"Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer\u2019s disease at the prodromal stage","volume":"89","author":"Bousiges","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.neurol.2022.03.008_bib0900","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/brainsci11020215","article-title":"Cerebrospinal fluid biomarkers of Alzheimer\u2019s Disease: current evidence and future perspectives","volume":"11","author":"McGrowder","year":"2021","journal-title":"Brain Sci"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib0905","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/JAD-140771","article-title":"Amyloid-beta 42\/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays","volume":"43","author":"Lewczuk","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib0910","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","article-title":"Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study","volume":"61","author":"Hampel","year":"2004","journal-title":"Arch Gen Psychiatry"},{"issue":"Pt.\u00a02","key":"10.1016\/j.neurol.2022.03.008_bib0915","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/brain\/awp280","article-title":"Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study","volume":"133","author":"Molano","year":"2010","journal-title":"Brain"},{"issue":"Suppl. 1","key":"10.1016\/j.neurol.2022.03.008_bib0920","article-title":"Mild cognitive impairment associated with underlying Alzheimer's disease versus Lewy body disease","volume":"18","author":"Boeve","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"10.1016\/j.neurol.2022.03.008_bib0925","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/alzrt274","article-title":"The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis","volume":"6","author":"Donaghy","year":"2014","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"10.1016\/j.neurol.2022.03.008_bib0930","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00702-006-0537-z","article-title":"CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies","volume":"113","author":"Bibl","year":"2006","journal-title":"J Neural Transm"},{"issue":"4","key":"10.1016\/j.neurol.2022.03.008_bib0935","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3233\/JAD-130107","article-title":"Cerebrospinal fluid Abeta1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels","volume":"36","author":"Slaets","year":"2013","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"10.1016\/j.neurol.2022.03.008_bib0940","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/01.wnl.0000249130.63615.cc","article-title":"Differences in neuropathologic characteristics across the Lewy body dementia spectrum","volume":"67","author":"Ballard","year":"2006","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.neurol.2022.03.008_bib0945","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3390\/diagnostics10121015","article-title":"A\/T\/(N) Profile in cerebrospinal fluid of Parkinson\u2019s Disease with\/without cognitive impairment and dementia with Lewy Bodies","volume":"10","author":"Bellomo","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"10.1016\/j.neurol.2022.03.008_bib0950","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1471-4159.2006.04404.x","article-title":"Amyloid beta peptide ratio 42\/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load","volume":"101","author":"Wiltfang","year":"2007","journal-title":"J Neurochem"},{"issue":"6","key":"10.1016\/j.neurol.2022.03.008_bib0955","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/archpsyc.64.6.718","article-title":"Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment","volume":"64","author":"Zhong","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.neurol.2022.03.008_bib0960","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cca.2014.01.007","article-title":"Distinction between mild cognitive impairment and Alzheimer's disease by CSF amyloid beta40 and beta42, and protein-conjugated acrolein","volume":"430","author":"Mizoi","year":"2014","journal-title":"Clin Chim Acta"},{"issue":"5","key":"10.1016\/j.neurol.2022.03.008_bib0965","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000100926","article-title":"Prediction of Alzheimer's disease using the CSF Abeta42\/Abeta40 ratio in patients with mild cognitive impairment","volume":"23","author":"Hansson","year":"2007","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib0970","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3233\/JAD-2011-111349","article-title":"Performance of abeta1-40, abeta1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment","volume":"29","author":"Parnetti","year":"2012","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"10.1016\/j.neurol.2022.03.008_bib0975","doi-asserted-by":"crossref","first-page":"a028035","DOI":"10.1101\/cshperspect.a028035","article-title":"Pathology of Neurodegenerative Diseases","volume":"9","author":"Dugger","year":"2017","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"10.1016\/j.neurol.2022.03.008_bib0980","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40035-017-0077-5","article-title":"Protein misfolding in neurodegenerative diseases: implications and strategies","volume":"6","author":"Sweeney","year":"2017","journal-title":"Transl Neurodegener"},{"issue":"6645","key":"10.1016\/j.neurol.2022.03.008_bib0985","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.neurol.2022.03.008_bib0990","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.parkreldis.2013.06.008","article-title":"The diagnostic utility of cerebrospinal fluid alpha-synuclein analysis in dementia with Lewy bodies - a systematic review and meta-analysis","volume":"19","author":"Lim","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"10.1016\/j.neurol.2022.03.008_bib0995","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1017\/S1041610215000447","article-title":"Use of CSF alpha-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders","volume":"27","author":"Wang","year":"2015","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"10.1016\/j.neurol.2022.03.008_bib1000","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.neulet.2008.11.015","article-title":"Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?","volume":"450","author":"Ohrfelt","year":"2009","journal-title":"Neurosci Lett"},{"issue":"11","key":"10.1016\/j.neurol.2022.03.008_bib1005","doi-asserted-by":"crossref","first-page":"e81654","DOI":"10.1371\/journal.pone.0081654","article-title":"The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease","volume":"8","author":"Kapaki","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2022.03.008_bib1010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2008.11.055","article-title":"CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease","volume":"1251","author":"Noguchi-Shinohara","year":"2009","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.neurol.2022.03.008_bib1015","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3233\/JAD-2009-0955","article-title":"Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders","volume":"16","author":"Spies","year":"2009","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"10.1016\/j.neurol.2022.03.008_bib1020","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/mds.23670","article-title":"Cerebrospinal fluid Tau\/alpha-synuclein ratio in Parkinson's disease and degenerative dementias","volume":"26","author":"Parnetti","year":"2011","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.neurol.2022.03.008_bib1025","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2010.12.001","article-title":"CSF alpha-synuclein does not differentiate between parkinsonian disorders","volume":"33","author":"Aerts","year":"2012","journal-title":"Neurobiol Aging"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib1030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3233\/JAD-2010-100186","article-title":"CSF alpha-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease","volume":"22","author":"Reesink","year":"2010","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.neurol.2022.03.008_bib1035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WAD.0b013e31823899cc","article-title":"Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease","volume":"26","author":"Tateno","year":"2012","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"10.1016\/j.neurol.2022.03.008_bib1040","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","article-title":"Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration","volume":"213","author":"Mollenhauer","year":"2008","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib1045","doi-asserted-by":"crossref","first-page":"e53250","DOI":"10.1371\/journal.pone.0053250","article-title":"Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy","volume":"8","author":"Wennstrom","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib1050","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13195-017-0276-4","article-title":"Differential role of CSF fatty acid binding protein 3, alpha-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia","volume":"9","author":"Chiasserini","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"10.1016\/j.neurol.2022.03.008_bib1055","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2022.03.008_bib1060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/alzrt255","article-title":"Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease","volume":"6","author":"Hansson","year":"2014","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"10.1016\/j.neurol.2022.03.008_bib1065","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/jnc.12331","article-title":"CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies","volume":"127","author":"Luo","year":"2013","journal-title":"J Neurochem"},{"issue":"3","key":"10.1016\/j.neurol.2022.03.008_bib1070","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","article-title":"alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study","volume":"10","author":"Mollenhauer","year":"2011","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2022.03.008_bib1075","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/jnc.14719","article-title":"Measurement of CSF alpha-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease","volume":"150","author":"Garcia-Ayllon","year":"2019","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib1080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13195-020-00684-5","article-title":"Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage","volume":"12","author":"Bousiges","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib1085","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/mds.27867","article-title":"Pathological influences on clinical heterogeneity in Lewy Body Diseases","volume":"35","author":"Coughlin","year":"2020","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib1090","first-page":"188","article-title":"Post mortem cerebrospinal fluid alpha-synuclein levels are raised in multiple system atrophy and distinguish this from the other alpha-synucleinopathies","volume":"45","author":"Foulds","year":"2012","journal-title":"Parkinson's disease and Dementia with Lewy bodies. Neurobiol Dis"},{"key":"10.1016\/j.neurol.2022.03.008_bib1095","doi-asserted-by":"crossref","first-page":"661117","DOI":"10.3389\/fneur.2021.661117","article-title":"Modulation of the Interactions Between alpha-Synuclein and Lipid Membranes by Post-translational Modifications","volume":"12","author":"Bell","year":"2021","journal-title":"Front Neurol"},{"issue":"10","key":"10.1016\/j.neurol.2022.03.008_bib1100","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/acn3.338","article-title":"Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies","volume":"3","author":"Fairfoul","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"10.1016\/j.neurol.2022.03.008_bib1105","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/acn3.50897","article-title":"alpha-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies","volume":"6","author":"Bongianni","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib1110","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40478-021-01175-w","article-title":"Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies","volume":"9","author":"Bargar","year":"2021","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib1115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","article-title":"Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC","volume":"6","author":"Groveman","year":"2018","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib1120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","article-title":"Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies","volume":"140","author":"Rossi","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurol.2022.03.008_bib1125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1742-2094-7-34","article-title":"In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases","volume":"7","author":"Bonneh-Barkay","year":"2010","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurol.2022.03.008_bib1130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1742-2094-3-27","article-title":"Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD","volume":"3","author":"Colton","year":"2006","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib1135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/acn3.266","article-title":"Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"8","key":"10.1016\/j.neurol.2022.03.008_bib1140","doi-asserted-by":"crossref","first-page":"e0135458","DOI":"10.1371\/journal.pone.0135458","article-title":"The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies","volume":"10","author":"Wennstrom","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.neurol.2022.03.008_bib1145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF02740632","article-title":"RC3\/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes","volume":"15","author":"Gerendasy","year":"1997","journal-title":"Mol Neurobiol"},{"issue":"19","key":"10.1016\/j.neurol.2022.03.008_bib1150","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/emboj.2009.273","article-title":"Long-term potentiation: two pathways meet at neurogranin","volume":"28","author":"Hayashi","year":"2009","journal-title":"EMBO J"},{"issue":"2","key":"10.1016\/j.neurol.2022.03.008_bib1155","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00401-010-0711-0","article-title":"The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia","volume":"120","author":"Schulz-Schaeffer","year":"2010","journal-title":"Acta Neuropathol"},{"issue":"1\u20132","key":"10.1016\/j.neurol.2022.03.008_bib1160","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1570-9639(02)00452-1","article-title":"Evidence for different functional properties of the neuronal calcium sensor proteins VILIP-1 and VILIP-3: from subcellular localization to cellular function","volume":"1600","author":"Spilker","year":"2002","journal-title":"Biochim Biophys Acta"},{"issue":"17","key":"10.1016\/j.neurol.2022.03.008_bib1165","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1523\/JNEUROSCI.22-17-07331.2002","article-title":"Reversible translocation and activity-dependent localization of the calcium-myristoyl switch protein VILIP-1 to different membrane compartments in living hippocampal neurons","volume":"22","author":"Spilker","year":"2002","journal-title":"J Neurosci"},{"issue":"10","key":"10.1016\/j.neurol.2022.03.008_bib1170","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1177\/0300060519860951","article-title":"Cerebrospinal fluid biomarkers and cognitive status in differential diagnosis of frontotemporal dementia and Alzheimer's disease","volume":"47","author":"Casoli","year":"2019","journal-title":"J Int Med Res"},{"issue":"1","key":"10.1016\/j.neurol.2022.03.008_bib1175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/WAD.0000000000000414","article-title":"Biomarker use for dementia with Lewy Body diagnosis: survey of US Experts","volume":"35","author":"Armstrong","year":"2021","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"9","key":"10.1016\/j.neurol.2022.03.008_bib1180","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1212\/WNL.0b013e3182a2cbd1","article-title":"Risk factors for dementia with Lewy bodies: a case-control study","volume":"81","author":"Boot","year":"2013","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.neurol.2022.03.008_bib1185","doi-asserted-by":"crossref","first-page":"956","DOI":"10.2174\/1567205018666211027143944","article-title":"Classification of patients with Alzheimer's Disease and dementia with Lewy Bodies using Resting EEG selected features at sensor and source levels: a proof-of-concept study","volume":"18","author":"San-Martin","year":"2021","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.neurol.2022.03.008_bib1190","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2021-327788","article-title":"Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer\u2019s disease, frontotemporal dementia and progressive supranuclear palsy","author":"Chouliaras","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722005604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722005604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:44:22Z","timestamp":1758519862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378722005604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":119,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0035378722005604"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2022.03.008","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers and diagnosis of dementia with Lewy bodies including prodromal: Practical aspects","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2022.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}